Kansas City, MO; White Marsh, MD; Bath, UK - Evogen, Inc., a global molecular diagnostics comopany, announced today that it is developing multi-faceted capabilities to address the air-monitoring, detection, and diagnosis of Influenza A H1N1, or Swine Flu, in addition to several prevalent flu types. Evogen’s molecular PCR diagnostic test is capable of rapidly and specifically detecting H1N1 pandemic Influenza, utilizing HyBeacons® technology. The test can be implemented on PCR equipment currently used in laboratories globally, or can be operated on Evogen’s EvoCyclerTM HD12, a rapid, portable, affordable PCR platform designed specifically for field use, when and where needed. The EvoCycler HD12, utilizing HyBeacons tests, provides High Definition PCR results in a simple-to-use molecular diagnostic system that can be implemented at the "front line" in this global pandemic. In addition, Evogen’s validated air-sampling systems designed for airborne pathogen collection may be effective in determining if the Influenza virus is present in the air and not just on surfaces. The combination of air samplers, the EvoCycler HD12 instrument and HyBeacons tests can be used as an integrated system to meet public health needs or used separately with other commercially available technologies. Additionally, tests for the full Influenza spectrum, Flu A, Flu B, Avian Flu (H5N1), Swine Flu (H1N1) and others are available to enable flu related diagnosis. "HyBeacons is a novel PCR chemistry able to more effectively detect multiple pathogen strains than other commonly used chemistries. This feature is critical to infectious disease detection for pathogens such as Influenza where a strain could shift to a highly pathogenic strain." said Sean Reineke, Evogen’s President and CEO. "The EvoCycler HD12 is aneal platform for bringing diagnostic capabilities to the time and place of need, given its portability, low cost and ease-of-use. In addition, our air sampling solutions are deployed in over 1000 locations worldwide as part of pathogen detection systems. Evogen is focused on delivering tailored systems specifically designed to enhance the decentralization of molecular diagnostics in a variety of fields, moving the capability for detection out to where it is needed. We are positioned to assist organizations involved in the front-line of detection, for infectious disease, biodefense or environmental monitoring applications." Evogen will request the U.S. Food and Drug Administration (FDA) to grant an Emergency Use Authorization for the specific H1N1 pandemic strain PCR test for use on a variety of platforms including the EvoCycler HD12 instrument as clinical testing is completed. Additionally, Evogen is seeking partners globally interested in validating the platform with currently existing technologies to ensure the most effective and affordable combinations are available to health care professionals, governments and military organizations. High Definition PCR High Definition PCR is enabled through the combination of HyBeacons assays operating on the EvoCycler HD12, an innovative instrument that combines ultra-rapid PCR amplification together with detection. Designed for clinical, research, environmental, and biodefense applications, the EvoCycler HD12 can simultaneously process, analyze andentify up to 12 samples in less than 30 minutes. The operator-intuitive instrument software automates key tasks, from selection of the most appropriate primers and thermal cycling conditions through to auto-calling of results. HyBeacons assays are designed to detect sections of DNA sequence with a genetic variation, crucial to specific pathogen detection. Together, EvoCycler and HyBeacons provide unsurpassed results in an easy-to-use, affordable, fieldable format. About Evogen (www.evogen.com) Evogen, Inc. is the culmination of the merger of two leading independent companies bringing together technologies to meet the ever-evolving needs of the molecular detection and diagnostics industry. Evogen, Ltd., a UK molecular diagnostics company and Sceptor Industries, Inc., a US aerosol collection systems company merged to form an entity uniquely positioned to provide accurate, rapid and affordable solutions globally for molecular detection and diagnostics across multiple markets including research, clinical, biodefense, environmental and animal health. Evogen, Inc. is globally positioned with offices in Kansas City, MO., White Marsh, MD and Bath, UK. For more information, visit www.evogen.com. Contacts: Sean Reineke, President and Chief Executive Officer Evogen, Inc. Phone: 301.466.2328 Email: sreineke@evogen.com Joanne Stephenson, Vice President, Corporate Business Development Evogen, Inc. Phone: 240.688.6615 Email: jstephenson@evogen.com